Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GNRHR | P30968 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | UBE2M | P61081 | 1/20 | 0.30 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3399483 | 0.89 | KDM4E (0.38) | KDM4EGNRHR | |
| SCHEMBL3400874 | 0.85 | HRH3 (0.36) | KDM4EGNRHR | |
| SCHEMBL3404520 | 0.71 | TACR2 (0.43) | KDM4E | |
| SCHEMBL5929244 | 0.70 | RXFP1 (0.40) | KDM4EL3MBTL1RXFP1LMNANPC1 | |
| SCHEMBL3400819 | 0.68 | HTR2C (0.46) | KDM4ELMNA | |
| SCHEMBL3405240 | 0.65 | HTR2C (0.45) | KDM4ELMNA | |
| SCHEMBL5928960 | 0.64 | GABRA1 (0.42) | KDM4ERXFP1LMNANPC1 | |
| SCHEMBL62698 | 0.63 | KDM4E (0.38) | KMT2AMEN1KDM4EL3MBTL1LMNA | |
| SCHEMBL5929020 | 0.62 | ALDH1A1 (0.36) | KMT2AMEN1KDM4ERXFP1LMNA | |
| SCHEMBL3402966 | 0.61 | MEN1 (0.39) | KMT2AMEN1KDM4ELMNAUBE2M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | LIGAND PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | HRH3, HRH4, HRH2 | KMT2A 890/4885MEN1 1347/4885KDM4E 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.